G L Hall1, A Compston, N J Scolding
1University of Cambridge Neurology Unit, Addenbrooke's Hospital, UK.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Interferon-beta (IFN-beta) is the first treatment to impact multiple sclerosis (MS) progression. This review examines IFN-beta mechanisms in demyelinating disease and proposes a treatment model for MS.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: